EP4701631A1 - Levothyroxindispersionen - Google Patents
LevothyroxindispersionenInfo
- Publication number
- EP4701631A1 EP4701631A1 EP24796417.4A EP24796417A EP4701631A1 EP 4701631 A1 EP4701631 A1 EP 4701631A1 EP 24796417 A EP24796417 A EP 24796417A EP 4701631 A1 EP4701631 A1 EP 4701631A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- levothyroxine
- pharmaceutically acceptable
- pharmaceutical
- pharmaceutical dispersion
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202311030765 | 2023-04-28 | ||
| PCT/IB2024/054111 WO2024224373A1 (en) | 2023-04-28 | 2024-04-27 | Levothyroxine dispersions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4701631A1 true EP4701631A1 (de) | 2026-03-04 |
Family
ID=93256005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP24796417.4A Pending EP4701631A1 (de) | 2023-04-28 | 2024-04-27 | Levothyroxindispersionen |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP4701631A1 (de) |
| WO (1) | WO2024224373A1 (de) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL292487A (en) * | 2019-11-01 | 2022-06-01 | Aquestive Therapeutics Inc | Compositions of medicinal meters and methods of treatment |
| US20250268830A1 (en) * | 2021-10-06 | 2025-08-28 | Pharmathen S.A. | Sustained release injectable pharmaceutical formulation of levothyroxine and process for preparation thereof |
-
2024
- 2024-04-27 EP EP24796417.4A patent/EP4701631A1/de active Pending
- 2024-04-27 WO PCT/IB2024/054111 patent/WO2024224373A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024224373A1 (en) | 2024-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3442586B1 (de) | Stabile parenterale nimopidinformulierung | |
| CN107810000B (zh) | 来氟米林的可注射药物组合物 | |
| US8481589B2 (en) | Taxoid-based compositions | |
| US10278946B2 (en) | Liquid formulation of cabazitaxel | |
| US20230201300A1 (en) | Stable intranasal formulations of carbetocin | |
| WO2024224373A1 (en) | Levothyroxine dispersions | |
| EP4192428A1 (de) | Phytonadionzusammensetzungen | |
| RU2861681C2 (ru) | Композиция наночастиц для быстрого суспендирования и способ ее получения | |
| WO2026062692A1 (en) | Ready to use injectable compositions of metolazone | |
| WO2024112860A1 (en) | Novel solution formulation of cyclophosphamide | |
| EP4531837A1 (de) | Lyophilisierte pharmazeutische zusammensetzungen von kupferhistidinat | |
| EP4025205A1 (de) | Flüssige formulierungen von cabazitaxel | |
| EP4676487A1 (de) | Injizierbare zusammensetzungen von metolazon | |
| NZ773548B2 (en) | Stable intranasal formulations of carbetocin | |
| WO2024127418A1 (en) | Injectable compositions of posaconazole | |
| WO2023148763A1 (en) | Injectable pharmaceutical compositions of azole antifungal agents | |
| HK40077694A (en) | Stable nimodipine parenteral formulation | |
| US20190274986A1 (en) | Sterile injectable composition comprising melphalan | |
| US20190275102A1 (en) | Sterile injectable composition comprising carfilzomib | |
| US20170128542A1 (en) | Non-aqueous glucagon formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20251127 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |